GSK, Cytokinetics Development Plan For Ispinesib Includes Dozens Of Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Several Phase II trials are proceeding studying the kinesin spindle protein inhibitor in breast, ovarian, prostate and melanoma cancers.